Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 5/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | CASP7 | P55210 | 1/20 | 0.63 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635997 | 0.94 | SMN1; SMN2 (0.73) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635998 | 0.94 | SMN1; SMN2 (0.76) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12636000 | 0.93 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635993 | 0.93 | SMN1; SMN2 (0.77) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635996 | 0.92 | SMN1; SMN2 (0.72) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635994 | 0.92 | SMN1; SMN2 (0.72) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635999 | 0.91 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12635984 | 0.90 | SMN1; SMN2 (0.68) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12636009 | 0.89 | SMN1; SMN2 (0.77) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 | |
| SCHEMBL12636003 | 0.89 | SMN1; SMN2 (0.73) | SMN1; SMN2TSHRPOLBKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939557-B2 | Vascular endothelial receptor specific inhibitors | NOVA SOUTHEASTERN UNIVERSITY (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939557-B2 | Vascular endothelial receptor specific inhibitors | NOVA SOUTHEASTERN UNIVERSITY (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2007124355-A2 | VASCULAR ENDOTHELIAL RECEPTOR SPECIFIC INHIBITORS | NOVA SOUTHEASTERN UNIVERSITY (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249575-A1 | VASCULAR ENDOTHELIAL RECEPTOR SPECIFIC INHIBITORS | NOVA SOUTHEASTERN UNIVERSITY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249575-A1 | VASCULAR ENDOTHELIAL RECEPTOR SPECIFIC INHIBITORS | NOVA SOUTHEASTERN UNIVERSITY (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249575-A1 | VASCULAR ENDOTHELIAL RECEPTOR SPECIFIC INHIBITORS | KDR, FLT4, FLT1 | SMN1; SMN2 4781/4885TSHR 1285/4885POLB 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.